Clinical trials: Hepatic Tumors
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency…
- Trial name
- NCT00617981
- Testing
- ThermoDox, 5% Dextrose Solution
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 701 people
- Sponsor
- Imunon
Hepatocellular Carcinoma
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
- Trial name
- HCC (NCT05408221)
- Testing
- Rulonilimab+Lenvatinib
- Where
- 5 sites in China
- Volunteers
- 576 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Hepatocellular Carcinoma
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
- Trial name
- NCT02854839
- Testing
- MG4101
- Where
- 6 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Carcinoma, Hepatocellular
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
The purpose of this study is to assess the safety and tolerability of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma (liver cancer).
- Trial name
- NCT00920192
- Testing
- Foretinib
- Where
- 7 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics (what the body does to the study medication) of JNJ-38518168 at approximately steady-state (stable medication levels) after administration of multiple oral 30 mg…
- Trial name
- NCT01863784
- Testing
- JNJ-38518168
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232633
- Testing
- BBI503
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hepatocellular Carcinoma (HCC)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with…
- Trial name
- EMERALD-Y90 (NCT06040099)
- Testing
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by…
- Trial name
- DCE-MRI (NCT01806740)
- Testing
- Gadoterate meglumine
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Guerbet
Hepatocellular Carcinoma
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
- Trial name
- NCT00273312
- Testing
- Patupilone
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Hepatocellular Carcinoma
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04741165
- Testing
- HX008, Bevacizumab, Lenvatinib
- Where
- 13 sites in China
- Volunteers
- 72 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Hepatocellular Carcinoma
Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line of systemic therapy.
- Trial name
- NCT03591965
- Testing
- ATG-008
- Where
- 30 sites in China, South Korea and 1 more
- Volunteers
- 73 people
- Sponsor
- Antengene Therapeutics Limited
Hepatocellular Carcinoma, Metastatic Cancer
Holmium-166 Retrospective Collection of Real-World Data
The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting…
- Trial name
- RECORD (NCT05111795)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
- Where
- 12 sites in Belgium, Germany and 5 more
- Volunteers
- 146 people
- Sponsor
- Terumo Europe N.V.
Recurrent Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation
Hepatocellular carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver…
- Trial name
- NCT02719782
- Testing
- Biological: TCR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
Liver Cirrhosis, Liver Cancer
Multi-analyte Blood Test Clinical Trial
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance.
- Conditions
- Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
- Trial name
- LIVER-1 (NCT05199259)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Hepatocellular Carcinoma
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
- Trial name
- NCT00165633
- Testing
- Menatetrenone
- Where
- 30 sites in Japan
- Volunteers
- 540 people
- Sponsor
- Eisai Limited
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience